Inhibrx (INBX) Director Kayyem Jon Faiz Receives Award

What Happened

• Kayyem Jon Faiz, a director of Inhibrx Biosciences, was granted 10,000 derivative awards (stock options) on June 3, 2026. The transaction is reported on an amended Form 4; the filing lists the option price as $0.00 and reports $0 total value for the recorded acquisition. This is an award/grant (transaction code A), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-03 (original Form 4 filed June 4, 2026; this is an amendment filed 2026-09-18 to correct the number of options).
• Quantity and type: 10,000 stock options (derivative instrument).
• Reported price/value: $0.00 per option; $0 reported acquisition value on the Form 4.
• Vesting/exercise condition: Footnote states the option "will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date."
• Shares owned after transaction: not specified in the information provided.
• Filing timeliness: Original Form 4 appears timely (filed the business day after the grant); this filing is an amendment to correct an administrative error.

Context

• This was an option grant (award) to a company director. For retail investors, grants are routine compensation for insiders; they do not represent an immediate market purchase or sale. The options do not appear to have been exercised or sold and will only become exercisable if the director remains in service through the stated vesting date. The amendment simply corrects the reported number of options granted.